发布: 2019年09月05日第9卷第17期 DOI: 10.21769/BioProtoc.3347 浏览次数: 5909
评审: Gal HaimovichAruna BitraRajesh Thippeshappa
Abstract
We describe here a detailed, refined protocol for the generation of citrulline-specific monoclonal antibodies from single human B cells from rheumatoid arthritis (RA) patients. This protocol provides a detailed guide of the procedure starting from single B cells of your choice and followed by amplification of the variable region of immunoglobulin genes by RT-PCR, subsequent immunoglobulin gene cloning, recombinant IgG1 monoclonal antibody (mAb) production and quality controls. The produced mAbs can be used for further studies including reactivity towards candidate antigens and functionality both in vitro and in vivo. This protocol can be used to generate antigen-specific mAbs from B cells derived from different tissues and compartments, including peripheral blood, synovial fluid, digested biopsies, bone marrow aspirations, and bronchoalveolar lavage fluid. Notably, although examples are given on how to identify citrulline-specific autoantibodies the general methods can also be applied to other reactivities.
Keywords: Autoantibodies (自身抗体)Background
Rheumatoid arthritis (RA) is an autoimmune disease affecting 0.5% to 1% of adults worldwide and can if left untreated lead to joint destruction and disability (Neovius et al., 2011). Anti-citrullinated protein autoantibodies (ACPA) are a hallmark of RA and can predict a more aggressive disease course in patients that belong to the positive subgroup. This autoreactivity is directed towards citrullination, an enzyme mediated post-translational modification changing the positively charged arginine to a neutral citrulline. Interestingly, serum ACPA IgG often precede the onset of disease (Rantapää-Dahlqvist et al., 2003; Nielen et al., 2004) and while recent discoveries have started to decipher their roles in the pathogenesis and suggested that APCA may directly mediate pathogenic effects such as pain, osteoclast differentiation, and monocyte pro-inflammatory response (Harre et al., 2012; Sokolove et al., 2014; Wigerblad et al., 2016; Krishnamurthy et al., 2016; Krishnamurthy et al., 2019), much remains to be elucidated. The generation of citrulline-specific monoclonal antibodies (mAbs) from single B cells obtained from RA patient material provides a valuable tool to better understand ACPA-mediated functionality, as well as the B-cell biology and the Immunoglobulin (Ig) gene repertoire during disease. However, when generating monoclonal antibodies from autoimmune patients, there are several technical challenges and important aspects to consider, especially regarding analysis of the citrulline fine-specificity of these produced mAbs.
Hence, here we describe a detailed, refined protocol for the generation of citrulline-specific mAbs from single B cells from RA patients. The protocol provides a detailed guide of the procedure starting from single-cell sorted B cells e.g., by flow cytometry, amplification of the variable region of immunoglobulin genes by RT-PCR, and subsequent immunoglobulin gene cloning and full recombinant IgG1 monoclonal antibody (mAb) production. This protocol is derived from strategies developed some years ago in the Nussenzweig’s laboratory and that has been widely applied for generation of human monoclonal antibodies (Wardemann et al., 2003; Tiller et al., 2008). However, this protocol also includes more detailed methods for quality controls, IgG production, purification, storage and specificity-screenings. These are things that we have found to be critical to avoid false positivity in assays and to be able to separate true strong antigen-specific reactivity from the polyreactivity commonly seen in autoimmune patients that can lead to incorrect conclusions (Amara et al., 2019). Since aggregation or poor-quality IgG can give false positivity in ELISA, we strongly recommend to avoid IgG preparations with low concentrations and that any positivity found in initial exploratory screenings is confirmed in larger scale IgG expression batches that are more rigorously quality control tested. Furthermore, although this collection of methods is providing in-house ELISA protocols for detection of citrulline reactivity we recommend using several methods in parallel for confirmation of reactivity (e.g., antigen-arrays, multiplex bead arrays, and/or commercial CCP2/CCP3 clinical ELISA kits). All screenings should use an IgG concentration of 5 μg/ml IgG or lower to avoid any false positivity and any identified positive clones should subsequently be titrated from 5 μg/ml to 50 ng/ml (or lower) to confirm binding. While the frequency of polyreactive B cells clones are relatively high in the B cell repertoire, especially in memory B cells carrying low SHM, our data suggest that the true antigen-specific clones are in contrast relatively rare also in the tissue.
Therefore, it may be favorable to use an enrichment strategy for antigen-specific B cells or defined B cells subsets (e.g., antigen-tetramer sorting) rather than a broad repertoire screening. However, these methods are not within the scope of this protocol. Notably, a majority of the high-binding ACPA clones identified so far (Lloyd et al., 2018; Titcombe et al., 2018; Steen et al., 2019) carry high level of somatic hypermutations and N-linked glycosylation sites in the variable regions and these features may also have an indicative value when identifying new positive mAbs.
With this method, it is possible for an experienced researcher to produce milligrams of human recombinant mAbs within a few weeks, providing a valuable tool for downstream functional studies both in vitro and in vivo. The capacity to produce and characterize antigen-specific mAbs is extremely useful for elucidating the interactions of particular antibodies and antigens and exploring B-cell immunology.
Materials and Reagents
Common list
Equipment
Common list
Software
Procedure
文章信息
版权信息
© 2019 The Authors; exclusive licensee Bio-protocol LLC.
如何引用
Amara, K., Israelsson, L., Stålesen, R., Sahlström, P., Steen, J., Malmström, V. and Grönwall, C. (2019). A Refined Protocol for Identifying Citrulline-specific Monoclonal Antibodies from Single Human B Cells from Rheumatoid Arthritis Patient Material. Bio-protocol 9(17): e3347. DOI: 10.21769/BioProtoc.3347.
分类
免疫学 > 抗体分析 > 抗体功能
分子生物学 > 蛋白质 > 分离
分子生物学 > DNA > DNA 克隆
您对这篇实验方法有问题吗?
在此处发布您的问题,我们将邀请本文作者来回答。同时,我们会将您的问题发布到Bio-protocol Exchange,以便寻求社区成员的帮助。
提问指南
+ 问题描述
写下详细的问题描述,包括所有有助于他人回答您问题的信息(例如实验过程、条件和相关图像等)。
Share
Bluesky
X
Copy link